Exercised Warrants Show Confidence in AI-Driven Healthcare Innovations
Source: Streetwise Reports  (7/29/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has successfully seen the exercise of nearly 800,000 warrants issued on conversion of special warrants in June for gross proceeds of about CA$500,000. See why one technical analyst rates this stock a Buy as the company solidifies its investor confidence. More >

Analyst Says CA Pharma Underappreciated by Investors
Source: Patrick Trucchio  (7/23/24)
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. More >

Analyst's Target Price for Biotech Massively Higher Than Current Price
Source: Dr. Leland Gershell  (7/22/24)
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price. More >

Study Shows 93% Cough Suppression With Co.'s Drug
Source: Streetwise Reports  (7/18/24)
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market." More >

Could This Stock Be the Next Bellus Cough Treatment?
Source: Clive Maund  (7/17/24)
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy. More >

LA Biotech Unveils New Patented Nicotinamide Riboside Chloride
Source: Dr. Raghuram Selvaraju  (7/15/24)
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report. More >

Healthcare AI Company Achieves Key Milestones and Secures New Partnerships
Source: Streetwise Reports  (7/11/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has provided a general corporate update, detailing significant progress made through Q1 and Q2 of 2024. Read about what this means for the future of its platform, the Global Library of Medicine (GLM) and future projects. More >

Biopharma Co. Reports Strong FQ224 Results Driven
Source: Dr. Douglas Loe  (7/11/24)
Leede Financial Inc. analyst Dr. Douglas W. Loe wrote he is maintaining his target price and Buy rating on Theratechnologies Inc. (TH:TSX). More >

Texas Biotech Announces Plans for Preclinical Obesity Studies
Source: Dr. Jonathan Aschoff  (7/8/24)
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note. More >

AI Health Stock Heading Higher Expert Says
Source: Clive Maund  (7/2/24)
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher. More >

New Patents and Strategic Partnerships Boost Smart Home Innovation
Source: Streetwise Reports  (7/1/24)
SKYX Platforms Corp. (SKYX:NASDAQ), a leader in smart platform technology, has announced the issuance of six additional patents in the U.S. and internationally, expanding its already robust patent portfolio to over 94 issued and pending patents globally. Find out how these partnerships affect upcoming projects and plans. More >

California Biotech Reports Positive Phase 3 Results
Source: Ed Arce  (6/25/24)
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients. More >

Major New Contract Marks Significant Milestone for Counter-Drone Tech Co.
Source: Streetwise Reports  (6/24/24)
DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has announced a significant new contract valued at AU$4.7 million from a non-government Swiss international customer. Find out why this is a major milestone for the company. More >

Chicago Alt. Medicine Co. Announces US$50M Share Repurchase Program
Source: Nick Anderson  (6/18/24)
In a Roth MKM research note, analyst Nick Anderson noted that Verano Holdings Corp. (VRNO:CSE; VRNOF:OTCQX) was well-positioned to generate increasing cash flow. More >

Clean Tech Subsidiary Finds Manufacturer for Wound Solution
Source: Streetwise Reports  (6/14/24)
BioLargo Inc. (BLGO:OTCQB) announced that subsidiary Clyra Medical Technologies Inc. has selected a company to support the manufacturing of its medical products, including its surgical wound irrigation solution, Bioclynse. See why one nonprofit group says the rate of healthcare-associated infections has remained high since the pandemic. More >

Is This Pharma Co. the Next Eli Lilly?
Source: Streetwise Reports  (6/11/24)
Nervgen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) is making significant strides in the field of nerve damage and spinal cord injury treatments. Find out about the company's future plans and why Chen Lin of What is Chen Buying? What is Chen Selling? said he believes Nervgen could potentially become the next Eli Lilly. More >

Positive Phase 2 Clinical Trial Results Announced for Drug Treating Idiopathic Hypersomnia
Source: Streetwise Reports  (6/10/24)
Zevra Therapeutics Inc. (ZVRA:NASDAQ), a company specializing in rare disease therapeutics, has announced positive final results from its Phase 2 clinical trial evaluating the safety and tolerability of KP1077 for treating idiopathic hypersomnia. More >

Rare Disease Co. Presents Positive Phase 2 KP1077 Data
Source: Dr. Jonathan Aschoff  (6/6/24)
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note. More >

Co. Targets More Verticals in Safe Supply
Source: Streetwise Reports  (6/5/24)
This Canadian firm, with a streaming business model, intends to invest in two additional segments of the safe supply ecosystem. Here, learn more about this approach to reducing harms from illegal drugs. More >

Strong Q1 2024 Financial Results Reflect Positive Growth For AI Company
Source: Streetwise Reports  (5/24/24)
MultiSensor AI Holdings, Inc. (NASDAQ: MSAI) announced strong financial results for the first quarter of 2024. Read on for more about how this plays out in its role within the AI sector. More >

Co. Expands Telehealth Contract to New State
Source: Streetwise Reports  (5/22/24)
Reliq Health Technologies Inc. announced that a large U.S. health group has expanded its contract with the telehealth company to cover facilities in a new state. Read why one analyst thinks the stock is a Buy. More >

New Healthcare AI Partnership Aims to Transform Health Risk Assessments
Source: Streetwise Reports  (5/21/24)
Treatment.com AI Inc. has entered into a collaborative agreement with Health Care Services International Inc. to leverage its advanced healthcare AI engine and enhance services. Read on to learn what this means for the growing sector. More >

Pharma Co. Secures $650M Strategic Financing
Source: Edward Nash  (5/16/24)
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine. More >

New COPD Drug Slated for Approval Decision This June
Source: Streetwise Reports  (5/15/24)
Ahead of the upcoming PDUFA date, several analysts recommend the biopharma behind this treatment as a Buy. Read on to learn why. More >

Pharma Stock Focuses on Successful Ensifentrine Launch
Source: Dr. Thomas Shrader   (5/15/24)
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note. More >